Ethypharm Digital Therapy (EDT) is a European Lifescience company, pioneered by entrepreneurial healthcare market specialists, who put their passion into agile ways of redefining disease management, offering personalised and clinically-proven digital therapies. 

Founded in 2021, EDT hold the exclusive rights in France, UK, Italy and Spain for deprexis®, the first digital psychotherapy for patients suffering from depression who are looking for immediate and 24/7 accessibility to psychotherapy. 

EDT through deprexis® are using a digital approach to transform the delivery of effective clinical therapy and to address some of the pressing agendas in the NHS. deprexis® can address the waiting times and capacity issues for access to psychological therapies, reduce service costs, even out inequalities of access and empower patients to manage their own care.

Ethypharm Digital Therapy SAS is fully owned by the Ethypharm Group.